Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$221000.0.

  • Adma Biologics' Change in Accured Expenses fell 1570.68% to -$221000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 5645.63%. This contributed to the annual value of -$1.1 million for FY2024, which is 11519.26% down from last year.
  • Latest data reveals that Adma Biologics reported Change in Accured Expenses of -$221000.0 as of Q3 2025, which was down 1570.68% from -$2.8 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Change in Accured Expenses peaked at $6.9 million during Q4 2022, and registered a low of -$6.0 million during Q2 2024.
  • Over the past 5 years, Adma Biologics' median Change in Accured Expenses value was $313905.0 (recorded in 2022), while the average stood at $886000.0.
  • In the last 5 years, Adma Biologics' Change in Accured Expenses skyrocketed by 184039.6% in 2023 and then crashed by 41101.04% in 2025.
  • Over the past 5 years, Adma Biologics' Change in Accured Expenses (Quarter) stood at $2.8 million in 2021, then skyrocketed by 143.96% to $6.9 million in 2022, then tumbled by 61.29% to $2.7 million in 2023, then soared by 59.52% to $4.2 million in 2024, then plummeted by 105.21% to -$221000.0 in 2025.
  • Its Change in Accured Expenses stands at -$221000.0 for Q3 2025, versus -$2.8 million for Q2 2025 and -$2.4 million for Q1 2025.